[Featured Stock] Hanmi Pharm Hits Upper Limit on Trillion-Won New Drug Technology Export

[Asia Economy Reporter Park Jihwan] Hanmi Pharm recorded the upper price limit following news of a technology export deal worth over 1 trillion won.

According to the Korea Exchange on the 5th, Hanmi Pharm closed trading on the KOSPI market at 360,500 won, up to the maximum price limit (29.91%). Hanmi Science, the largest shareholder of Hanmi Pharm, also rose to the maximum price limit (29.85%) on the same day.

Yuhan Corporation, which previously exported a similar therapeutic candidate, also saw a 15.73% increase as the value of the new drug was re-evaluated.

Earlier, after the market closed on the 4th, Hanmi Pharm announced that it had signed a technology transfer contract for a biopharmaceutical to treat non-alcoholic steatohepatitis (NASH) with global pharmaceutical company Merck Sharp & Dohme (MSD). The total technology export amount is $870 million (approximately 1.0392 trillion won). Milestones for clinical development, approval, and commercialization stages amount to a total of $860 million. Double-digit royalties based on net sales will be received separately.

Sun Minjung, a researcher at Hana Financial Investment, commented, "Merck appears to have entered into the contract after analyzing the results of Phase 2 clinical trials conducted by Janssen and confirming the potential as a NASH treatment," adding, "Hanmi Pharm's technology transfer confirmed that the process does not end even if the technology is returned."

This content was produced with the assistance of AI translation services.